Li, Zhaoyan
Zhang, Guangtao
Cao, Nida
Xu, Jingjuan
Dong, Jiahuan
Li, Jia
Zhu, Xiaohong
Xu, Yan
Han, Chen
Wang, Rui
Xia, Xiang
Zhao, Gang
Huan, Xiangkun
Fan, Jin
Zhao, Aiguang
Funding for this research was provided by:
the Ministry of Science and Technology National Key Research and Development Program (2017YFC1700605)
Article History
Received: 13 May 2021
Accepted: 8 January 2022
First Online: 21 January 2022
Declarations
:
: Before the implementation of the study, the protocol of this study has been approved by the Ethics Committees of Longhua Hospital, Shanghai University of TCM (the version of the protocol [version 1.0] and approval number: 1943) and by the Ethics Committee of two other participating hospitals. Participants in the trial will provide written consent prior to participation. In 27 June 2019, the chemotherapy regimen of Xelox and FLOT added into the protocol by the principal investigator with the approval of the ethics committees of Longhua Hospital, Shanghai University of TCM.
: Not applicable
: The authors declare that they have no competing interests.